CSI Market
Sign In | Register

Aratana Therapeutics (PETX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access PETX Annual Cash Flow →
The cash flow figures below highlight longer-term patterns in how Aratana Therapeutics manages cash inflows and outflows over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2019)
3 Months 		(Dec 31 2018) (Sep 30 2018) (Jun 30 2018) (Mar 31 2018)
Operating Activities
Income-6.79
Depreciation & amortization0.26
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Impairment of Intangible Assets, Finite-lived0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.60
Research and Development in Process0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation2.31
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Research And Development Asset Acquired Other Than Through Business Combination Written Off-
Impairment Of Intangible Assets Excluding Goodwill-
Variable Interest Entity Initial Consolidation Gain Or Loss-
Increase Decrease In Licensing And Collaboration Commitment-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-2.66
Increase (Decrease) in Accounts Payable0.06
Increase (Decrease) in Accrued Liabilities-0.01
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.65
Other Working Capital0.09
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-5.49
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Payments to Acquire Marketable Securities0.00
Payments for Derivative Instrument, Investing Activities0.00
Payments For Intangible Assets Milestones-
Payments For Proceeds From Acquisition Of Investments-0.50
Payments For Proceeds From Sale Maturity And Collection Of Investments1.24
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.74
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.03
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.15
Proceeds From License Agreement Net Of Commission-
Payments Of License Agreement Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-0.12
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-5.49
Total Cash Flow0.00
4 historic quarters locked

Sign in to unlock the full Aratana Therapeutics cash flow history.

Sign In Create Free Account

About PETX Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.